AzTrials
AzTrials

Bariatric Surgery CandidateNCT02735564

Change in Reward System Activation and Gut Microbiota Following RYGB and Sleeve Gastrectomy for Weight Loss vs. Control-Heads Up Ancillary

A study testing Bariatric Surgery in people with Bariatric Surgery Candidate, run by Pennington Biomedical Research Center at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Bariatric surgery is considered an effective long-term intervention for the treatment of obesity and associated complications. While bariatric surgery has been shown to result in a large sustained weight loss, the degree of weight loss and maintenance thereafter varies greatly. Read more about this study

Who is it for?
Ages 21 to 70 yearsHealthy volunteers can take part
Conditions the study is for
Bariatric Surgery Candidate
What is being tested?
Bariatric Surgery
Type of treatment
Surgery or procedure
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
6 participants
Where
1 siteUnited States
Study dates
Apr 2016to Apr 2018
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 21 to 70 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Surgical Groups (RYGB and SG) Inclusion criteria for the two surgery groups (n=16)
  • Individuals who qualify for Heads Up and would like to participate in this ancillary study
  • Be willing to participate in additional procedures including: 4 brains scans (2 before surgery and 2 after surgery), 2 meal challenges (1 before surgery and 1 after surgery), and 2 microbiota collections (1 before surgery and 1 after surgery).
  • Be willing to archive microbiota samples
  • Control Group:
  • Males and females age 21-70 years
Show all 10Show fewer
  • Body Mass Index ≥40 kg/m2 without type 2 diabetes or ≥35 kg/m2 and ≤ 60kg/m² with type 2 diabetes
  • Agree to receive frequent contacts from investigators and communicate with program staff for up to 6 months
  • Able to give written informed consent
  • Able to comply with study procedures

Who cannot join

  • Unable or unwilling to give informed consent
  • Pregnant or planning on becoming pregnant during the 6 months you participate in the study
  • History or presence of unremoveable metal objects (medical or dental) or electronic devices or other contraindication to MRI scanning.
  • Unwillingness to complete an MRI due to confined space or other related phobias
  • Unable or unwilling to give informed consent
  • Hospitalization for psychiatric illness or substance use/abuse within the past year
Show all 17Show fewer
  • Diagnosis of schizophrenia, other psychotic disorders, bipolar disorder, or personality disorder as determined by the medical staff
  • Travel plans that do not permit participation
  • Pregnant or planning on becoming pregnant during the 6 months you participate in the study
  • History of prior bariatric surgery, extensive bowel resection, or hiatal hernia repair (unless approved by the medical staff)
  • History of eating disorder such as anorexia nervosa, bulimia, or binge eating (unless approved by program staff)
  • Current major depressive episode or history of suicidal behaviors
  • Severe congestive heart failure (NYHA class III, IV)
  • Second degree or greater heart block
  • Other medical, psychiatric, or behavioral limitations that in the judgement of the investigator may interfere with program participation or the ability to follow the intervention protocol
  • History or presence of unremoveable metal objects (medical or dental) or electronic devices or other contraindication to MRI scanning.
  • Unwillingness to complete an MRI due to confined space or other related phobias

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Pennington Biomedical Research Center

    Baton Rouge, Louisiana, 70808-4124

Other trials in United States

About this study

Official title: Change in Reward System Activation and Gut Microbiota Following Roux-en-y and Sleeve Gastrectomy for Weight Loss as Compared to a Control- Heads Up Ancillary

Bariatric surgery is considered an effective long-term intervention for the treatment of obesity and associated complications. While bariatric surgery has been shown to result in a large sustained weight loss, the degree of weight loss and maintenance thereafter varies greatly. The Heads Up Surgical Demonstration Project (Heads Up) is a 5 year project examining weight loss after an intensive medical intervention (IMI) and the 2 most widely used bariatric surgeries (roux-en-y gastric bypass or RYGB and sleeve gastrectomy or SG). Baseline data are collected prior to surgery and follow-up data are collected at 6 months and annually thereafter. A recent meta-analysis revealed that RYGB resulted in greater weight loss and is more effective in resolving obesity related comorbidities than SG, although SG has been shown to result in a reduction of perioperative complications and reoperations1. Full elucidation of the mechanisms leading to variation in success for weight loss interventions is crucial to understanding the most effective and reliable treatments for obesity and associated comorbidities.

Being tested
Bariatric Surgery
Keywords
Weight Loss, Magnetic Resonance Imaging, gut microbiota
Medical subject headings
Weight Loss

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Bariatric SurgeryProcedure or surgery

Study groups in NCT02735564
Study groupRoleWhat they receive
RYGBExperimentalBariatric Surgery:Roux-en-y
Receives: Procedure: Bariatric Surgery
SGExperimentalBariatric Surgery: Sleeve Gastrectomy
Receives: Procedure: Bariatric Surgery
ControlPlacebo comparatorBMI matched control
Receives: Procedure: Bariatric Surgery

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Neural reward sensitivity

    Investigate change in reward activation patterns in the brain in response to food cues using fMRI.

    Measured: baseline, 6 months

  2. gut microbiota

    Determine if gut microbiota, as analyzed via stool sample collection, changes from baseline (prior to surgery) to 6 months follow-up (post-surgery) among the groups.

    Measured: baseline, 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Apr 2016 (estimated)
  2. Study startApr 2016
  3. Primary completionNov 2017
  4. Study completionApr 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
6 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02735564
Sponsor's protocol ID
PBRC 2015-064
Status last verified
Jan 2020
First submitted
6 Apr 2016
Last updated
6 Jan 2020
Results posted
No
Data monitoring committee
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Bariatric Surgery in people with Bariatric Surgery Candidate, run by Pennington Biomedical Research Center at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 10 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 6 Jan 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Neural reward sensitivity (time frame: baseline, 6 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jan 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in